return to top button

INCLISIRAN (LEQVIO®)


















  • Values are % change from baseline over 510 days
  • Average baseline LDL was 105 mg/dl
  • Reference [1]
Lipid effects in patients with ASCVD on maximally tolerated statin
Parameter Inclisiran
(N=781)
Placebo
(N=780)
LDL -51% +1%
Total -34% 0%
Non-HDL -47% 0%
ApoB -45% -2%

  • Values are % change from baseline over 510 days
  • Average baseline LDL was 153 mg/dl
  • Reference [1]
Lipid effects in patients with HeFH on maximally tolerated statin
Parameter Inclisiran
(N=242)
Placebo
(N=240)
LDL -40% +8%
Total -25% +7%
Non-HDL -35% +7%
ApoB -33% +3%




  • Includes pain, erythema, and rash
  • Reference [1]
Side effect Inclisiran
(N=1833)
Placebo
(N=1822)
Injection site reactions 8.2% 1.8%
Arthralgia 5% 4%
UTI 4.4% 3.6%
Diarrhea 3.9% 3.5%
Bronchitis 4.3% 2.7%
Pain in extremity 3.3% 2.6%
Dyspnea 3.2% 2.6%